First slide

The leading science technology company Thermo Fisher Scientific announce an exclusive license agreement with MSAID GmbH, a software company transforming proteomics with deep learning, to develop and commercialize deep learning tools for proteomics. The agreement will make MSAID’s Prosit-derived framework widely accessible to proteomics laboratories.

  • The new algorithm allows gains in confidence and reproducibility and will be released as part of Thermo Fisher’s newest Thermo Scientific Proteome Discoverer 2.5 software release.
  • The availability of deep learning tools will enable improved confidence in proteomics research results, primarily in the areas of protein profiling using label-free or tandem mass tag (TMT)-based quantification, and a variety of new applications
  • Users can now access deep-learning-based prediction of tandem mass spectra, allowing for the formation of entire spectral libraries on demand and facilitating the identification of peptides with up to 10 times higher confidence and the extraction of more identifications from proteomics datasets via intensity-based rescoring.

The major investments and deals by Thermo Fisher Scientific in last six months are mentioned below:

May 2020: Thermo Fisher Scientific announced that it is constructing a new commercial manufacturing site in Plainville, Mass, the USA. The $180 million facility will double the company’s commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines.

April 2020:, Thermo Fisher Scientific, announced the availability of Thermo Scientific AcroMetrix Coronavirus 2019 RNA Control, its latest quality control product to monitor and validate COVID-19 molecular diagnostic tests. Thermo Fisher, in an effort to combat the Coronavirus outbreak, designed and developed a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests.

March 2020: Thermo Fisher Scientific, had signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) for cancer.
March 2020: Thermo Fisher Scientific announced acquisition of QIAGEN N.V., leading global provider of molecular diagnostics and sample preparation technologies for approximately $11.5 billion.

February 2020: Thermo Fisher Scientific announced collaboration with NanoPin Technologies, a leading developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood samples to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.

December 2019: Thermo Fisher Scientific, announced the opening of its $90 million viral vector CDMO (contract development and manufacturing organization) site in Massachusetts. The new Viral Vector Manufacturing Site will create 200 new jobs in Massachusetts. The 50,000-square-foot facility of Thermo Fisher Scientific will support the development, testing and manufacture of viral vectors, which are critical to advancing new life-saving gene and cell therapies.

November 2019: Thermo Fisher Scientific, announced an investments of around $24 million in its Inchinnan, Scotland, site to expand global bioproduction capabilities. The investment will increase large-volume liquid manufacturing capacity for cell culture media.

October 2019: Thermo Fisher Scientific Inc. had completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility from GlaxoSmithKline (GSK) for $102 million.

About Thermo Fisher Scientific
Thermo Fisher Scientific is a world leader in serving science, headquartered in Massachusetts, United States. The company has more than 75,000 colleagues across the globe to help the company to accelerate its life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. The company provides innovative technologies, purchasing convenience and pharmaceutical services through its premier brands like- Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Prominent Global Investors

View all

Related News